Skip to content

Effect of drug colistin in newborn infection.

To study the efficacy and outcome of intravenous colistin therapy in culture positive multidrug resistant or extensively drug resistant sepsis in outborn neonates.A prospective observation study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/02/103436
Enrollment
80
Registered
2026-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B96- Other bacterial agents as the cause of diseases classified elsewhere Health Condition 2: B961- Klebsiella pneumoniae [K. pneumoniae] as the cause of diseases classified elsewhere Health Condition 3: B962- Escherichia coli [E. coli ] as thecause of diseases classified elsewhere Health Condition 4: B965- Pseudomonas (aeruginosa) (mallei)(pseudomallei) as the cause of diseases classified elsewhere Health Condition 5: B968- Other specified bacterial agents as the cause of di

Interventions

Intervention1: Nil: Nil

Sponsors

Chacha Nehru Bal Chikitsalaya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All neonates with confirmed positive culture of any sterile body fluid like blood, respiratory ,urinary tract caused by multidrug or extensively drug resistant gram negative bacteria and susceptibility confirmed to colistin

Exclusion criteria

Exclusion criteria: Children with major congenital anomalies, severe renal dysfunction at baseline . Cases with colistin administered less than 48 hours. Cases with CSF culture emerged multidrug or extensively drug resistant organisms

Design outcomes

Primary

MeasureTime frame
Clinical cure at day 14 (defined as resolution of symptoms or signs of infection without need of antibiotic change or escalation.Timepoint: Clinical cure at day 14 (defined as resolution of symptoms or signs of infection without need of antibiotic change or escalation.

Secondary

MeasureTime frame
Microbiological Eradication as repeat culture report negative for Multidrug or Extensively drug resistant organisms.Timepoint: 72 hour , day 7 , day 14;All cause mortalities.Timepoint: 48 hours to 14 days or till Discharge.;Neonates developing Acute Kidney Injury as per N KDIGOTimepoint: 24 hour , 72 hour , day 7;Neonates developing hypocalcemia ,hypomagnesemia & dyselectrolytemia.Timepoint: 24 hour ,72 hour , day 7;Neonates requiring additional antibiotics in monotherapy group.Timepoint: starting of therapy to end of therapy

Countries

India

Contacts

Public ContactGoutham Shivarag

Chacha Nehru Bal Chikitsalaya

goutham007vv@gmail.com7907593387

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026